New Strategies for the Management of Community-Acquired Pneumonia
Claude Carbon, MD
Internal Medicine Unit, Bichat-Claude Bernard Hospital, Paris, France
Community-acquired pneumonia (CAP) remain potentially severe infections. New information regarding epidemiology, resistance of major pathogens to antimicrobials, and assessment of initial severity have occurred during the last ten years. The introduction of fluoroquinolones, with improved activity against Streptococcus pneumoniae and exhibiting a good level of efficacy against most of the pathogens responsible for CAP, represents a potential important step in the management of this condition. Caution should be taken to observe an optimal strategy of use, with careful selection of the compound in terms of tolerance. Cost-effectiveness studies are also required. The place of levofloxacin in this strategy is discussed.